Soluble immune response suppressor polypeptides and treatment of multiple sclerosis and other autoimmune diseases
AssigneeBoard of Regents, The University of Texas System
InventorStaley A. Brod
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating multiple sclerosis, type 1 diabetes mellitus and other autoimmune diseases by administering a soluble immune response suppressor (SIRS) peptide or a variant thereof to an individual having such disease. The SIRS peptide or variant reduces the severity of or frequency of relapse of multiple sclerosis and reduces the inflammation associated with multiple sclerosis and other autoimmune diseases.
Claims48
A method of immunotherapy in an individual comprising orally administering to the individual a therapeutically effective amount of a SIRS polypeptide comprising the N-terminal amino acid sequence (SEQ ID NO:5):
- X1-X2-X3-X3-X4-X4-X4-X4-X4-X4-Pro-X5-X2-X2-X6-X4-X4-X7-X7-X3-X4
- wherein X1 is Met, Val, Leu or Cys;
- X2 is Thr, Ala or Gly;
- X3 is Glu, Arg, Asp or Lys;
- X4 is Gln, Ser, Asn or Gly;
- X5 is Glu, Arg, Asp or Lys;
- X6 is Ile, Leu, Val, Met or Thr, and;
- X7 is Ala, Cys, Thr or Gly, and
- wherein said polypeptide is not SIRS-a7, SIRS-a6 or SIRS-a5.
A method for treating or preventing Type 1 diabetes or multiple sclerosis in an individual comprising administering to the individual a therapeutically effective amount of a SIRS polypeptide comprising the N-terminal amino acid sequence (SEQ ID NO:5):
- X1-X2-X3-X3-X4-X4-X4-X4-X4-X4-Pro-X5-X2-X2-X6-X4-X4-X7-X7-X3-X4
- wherein X1 is Met, Val, Leu or Cys;
- X2 is Thr, Ala or Gly;
- X3 is Glu, Arg, Asp or Lys;
- X4 is Gln, Ser, Asn or Gly;
- X5 is Glu, Arg, Asp or Lys;
- X6 is Ile, Leu, Val, Met or Thr, and;
- X7 is Ala, Cys, Thr or Gly, and
- wherein said polypeptide is not SIRS-a7, SIRS-a6 or SIRS-a5.
Dependencies are inferred from the claim text.